Cargando…
Metformin targets multiple signaling pathways in cancer
Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple s...
Autores principales: | Lei, Yong, Yi, Yanhua, Liu, Yang, Liu, Xia, Keller, Evan T., Qian, Chao-Nan, Zhang, Jian, Lu, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270304/ https://www.ncbi.nlm.nih.gov/pubmed/28126011 http://dx.doi.org/10.1186/s40880-017-0184-9 |
Ejemplares similares
-
Wnt3a: functions and implications in cancer
por: He, Sha, et al.
Publicado: (2015) -
Metformin promotes cGAS/STING signaling pathway activation by blocking AKT phosphorylation in gastric cancer
por: Shen, Qian, et al.
Publicado: (2023) -
Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
por: Pan, Yong-hong, et al.
Publicado: (2018) -
Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells
por: Olokpa, Emuejevoke, et al.
Publicado: (2022) -
IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker
por: Chen, Qiuyan, et al.
Publicado: (2016)